PTC Therapeutics, Inc. (NASDAQ:PTCT) was the recipient of some unusual options trading on Tuesday. Stock investors purchased 27,477 put options on the stock. This represents an increase of Infinity compared to the typical daily volume of 0 put options.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. American International Group Inc. grew its position in PTC Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 20,480 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 1,355 shares during the last quarter. Alps Advisors Inc. grew its position in PTC Therapeutics by 5.6% during the 2nd quarter. Alps Advisors Inc. now owns 31,191 shares of the biopharmaceutical company’s stock worth $572,000 after acquiring an additional 1,667 shares during the last quarter. Voya Investment Management LLC grew its position in PTC Therapeutics by 12.8% during the 2nd quarter. Voya Investment Management LLC now owns 16,459 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 1,866 shares during the last quarter. ProShare Advisors LLC grew its position in PTC Therapeutics by 8.9% during the 2nd quarter. ProShare Advisors LLC now owns 24,115 shares of the biopharmaceutical company’s stock worth $442,000 after acquiring an additional 1,970 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its position in PTC Therapeutics by 3.0% during the 1st quarter. TIAA CREF Investment Management LLC now owns 96,318 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 2,774 shares during the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

Several equities analysts recently issued reports on the company. Zacks Investment Research lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. ValuEngine lowered PTC Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 7th. Bank of America Corporation lowered PTC Therapeutics from a “neutral” rating to an “underperform” rating in a research note on Thursday, October 26th. William Blair assumed coverage on PTC Therapeutics in a research note on Wednesday, August 23rd. They set a “market perform” rating and a $17.00 price target on the stock. Finally, Cowen and Company restated a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, October 25th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $18.75.

Shares of PTC Therapeutics (NASDAQ:PTCT) opened at $15.88 on Friday. PTC Therapeutics has a 12 month low of $8.12 and a 12 month high of $22.00. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.97 and a current ratio of 3.08.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/17/traders-purchase-high-volume-of-ptc-therapeutics-put-options-ptct.html.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.